[Treatment of hyaline membrane disease with the plasminogen urokinase combination]

Area of Science:

• Neonatal Medicine
• Pulmonology
• Pharmacology

Background:

• Respiratory distress syndrome (RDS) is a significant cause of mortality in premature infants.
• Current therapeutic options for RDS have limitations in improving survival rates and disease progression.

Purpose of the Study:

• To evaluate the efficacy of a plasminogen-urokinase therapeutic combination in premature infants with respiratory distress.
• To assess the impact of this therapy on survival rates and duration of oxygen support.

Main Methods:

• A cohort of 14 premature infants diagnosed with respiratory distress was treated with plasminogen-urokinase in vivo.
• Survival rates and duration of oxygen therapy were recorded and compared to historical controls.

Main Results:

• The therapeutic combination achieved an 86% survival rate, a notable increase compared to conventional treatments.
• Infants receiving plasminogen-urokinase required shorter durations of oxygen therapy.
• The treatment appeared to limit the progression and extent of the respiratory disease.

Conclusions:

• Plasminogen-urokinase represents a promising therapeutic strategy for managing respiratory distress in premature neonates.
• This treatment offers improved survival benefits and reduces the burden of prolonged respiratory support.